Biosimilar Payments Under Medicare: On Closer Look, Is It Worth It?

The Medicare Part B reimbursement scenario for biosimilars may offer limited incentives to marketers considering investing in follow-on products, according to Foley Hoag attorney Jayson Slotnik.